Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting

• Main Authors: Ana Muntañola (Author), José María Arguiñano‐Pérez (Author), Julio Dávila (Author), Sonia González deVillambrosia (Author), Cecilia Carpio (Author), Ana Jiménez‐Ubieto (Author), Antonio Salar (Author), the GELTAMO (Grupo español de linfomas y trasplante de médula ósea) (Author)
• Format: Book
• Published: Wiley, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Although rituximab is generally well‐tolerated, infusion‐related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low‐speed infusion rates have been recommended. Consequently, intraven...